A method for evaluating treatment outcome in a patient having a genetic predisposition for a malignant neoplasm before clinical manifestation of the neoplasm can be seen radiographically. The method permits visualization of any tumor, whether located externally on a patient's body or located internally in the body, and as small as 2 mm in diameter, using a biomarker. The method uses biomarkers conjugated with nanoparticles which include but are not limited to quantum dots, with the conjugated form collectively termed functionalized nanoparticles, that are heated under specified conditions to produce a photoacoustic signal that is then visualized to locate and/or treat the tumor.

Provided herein are lipidoids that may be prepared from the conjugate addition of alkylamines to acrylates. In some embodiments, provided lipidoids are biodegradable and may be used in a variety of drug delivery systems. Given the amino moiety of the lipidoids, they are well-suited for the delivery of polynucleotides, in addition to other agents. Nanoparticles containing the inventive lipidoids and polynucleotides have been prepared and have been shown to be effective in delivering siRNA.

Provided are compositions and formulations comprising an isolated Staphylococcus aureus peptidoglycan sacculus comprising an azide-modified D-amino acid and an immunogenic polypeptide attached thereto. The composition can optionally also comprise an adjuvant. Also provided are methods for inducing an immune response in a subject using such compositions and formulations. Kits are also provided.

Technical field The invention relates to new calibrated-size gas-filled microvesicles bearing an overall positive charge, to their use and to their method of manufacturing. The gas-filled microvesicles have a geometric standard deviation (GSD) value of at least 1.25 or lower and a stabilizing envelope comprising an amphiphilic material, said amphiphilic material comprising a cationic lipid and a neutral or cationic amphiphilic polymeric compound.

The present invention relates to a nanoparticle composition for pulmonary drug delivery and, more specifically, to a drug delivery composition useful for specifically delivering a drug into the lungs, wherein the drug delivery composition comprises drug-bearing nanoparticles in which a complex of an anionic drug and a specific lipid is encapsulated inside nanoparticles formed by an amphiphilic block copolymer.

A method for preparing nanohydrogels comprising a dispersion step, in which a polysaccharide functionalized with hydrophobic molecules and in the form of a macromolecular agglomerate is dispersed in an aqueous solution, and a heating step, in which the aqueous dispersion of the polysaccharide is subjected to a temperature of between 70 C. and 150 C. and a pressure of between 1 bar and 5 bar. In the heating step, the conditions of temperature and pressure must be such that boiling of the aqueous dispersion of the polysaccharide does not take place.

Compositions useful for target detection, imaging and treatment, as well as methods of production and use thereof, are disclosed herein.

Methods, systems, and devices are disclosed for fabricating and implementing nanoscale and microscale structured carriers to provide guided, targeted, and on-demand delivery of molecules and biochemical substances for a variety of applications including diagnosis and/or treatment (theranostics) of diseases in humans and animals. In some aspects, a nanostructure carrier can be synthesized in the form of a nanobowl, which may include an actuatable capping particle that can be opened (and in some implementations, closed) on demand. In some aspects, a nanostructure carrier can be synthesized in the form of a hollow porous nanoparticle with a functionalized interior and/or exterior to attach payload substances and substances for magnetically guided delivery and controlled release of substance payloads.

The invention provides nanoparticle-stabilized nanocapsules, and methods of their preparation and use in delivery of therapeutics, such as nucleic acids. Various embodiments disclosed relate to a nanoparticle-stabilized nanocapsule. Various embodiments disclosed relate to nanoparticle-stabilized nanocapsules for nucleic acid delivery into cells. Various embodiments provide methods of using the nanocapsule for in vivo delivery of the nucleic acid materials.

This document relates to methods and materials involved in delivering molecules to a mammal. For example, methods and materials for using nanoparticles to increase the half-life and the bioavailability of molecules administered to a mammal are provided.